Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

In English

Författare

  • Bengt Simonsson
  • Tobias Gedde-Dahl
  • Berit Markevarn
  • Kari Remes
  • Jesper Stentoft
  • Anders Almqvist
  • Mats Bjoreman
  • Max Flogegard
  • Perttu Koskenvesa
  • Anders Lindblom
  • Claes Malm
  • Satu Mustjoki
  • Kristina Myhr-Eriksson
  • Lotta Ohm
  • Anu Rasanen
  • Marjatta Sinisalo
  • Anders Sjalander
  • Ulla Stromberg
  • Ole Weiss Bjerrum
  • Hans Ehrencrona
  • Franz Gruber
  • Veli Kairisto
  • Karin Olsson
  • Fredrik Sandin
  • Arnon Nagler
  • Johan Lanng Nielsen
  • Henrik Hjorth-Hansen
  • Kimmo Porkka
Visa allt

Summary, in English

Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg-IFN-alpha 2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg-IFN-alpha 2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg-IFN-alpha 2b treatment (< 12-week MMR rate 67%, > 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg-IFN-alpha 2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg-IFN-alpha 2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent. (Blood. 2011;118(12):3228-3235)

Publiceringsår

2011

Språk

Engelska

Sidor

3228-3235

Publikation/Tidskrift/Serie

Blood

Volym

118

Issue

12

Dokumenttyp

Artikel i tidskrift

Förlag

American Society of Hematology

Ämne

  • Hematology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1528-0020